Oral pulsed high-dose dexamethasone therapy for rheumatic diseases: An alternative safe and effective scheme.

To the Editor, Since its discovery by Kendall and Hench in 1950, glucocorticoids have been widely prescribed for the treatment of rheumatic diseases, although it has been recognized that this drug may be a double-edged sword. For example, suppose, on the one hand, it has a rapid and potent anti-inflammatory action that may be lifesaving, on the other hand. Unfortunately, in that case, it has various side effects, such as cushingoid facies, hyperglycemia, dyslipidemia, osteoporosis, myopathy, hypertension, and acne, among others. Several strategies have been designed aiming to obtain the best possible results from this treatment with minimum collateral effects. Glucocorticoid pulse therapy has emerged as an option and has been used to control severe disease activity quickly. It is traditionally used as 1000 mg methylprednisolone/day for 3 days, although it has been recognized that lower doses may be as effective. The use of the intravenous route has been associated with cardiovascular collapse, hypokalemia, and myocardial infarction [1]. Although the intravenous route is the most popular form of administration for pulse therapy, this treatment can also be done using the oral route or intramuscular injections. Dexamethasone has been frequently used in oral administration due to its low mineralocorticoid action. Oral pulse therapy (OPT) has been commonly used in dermatology for alopecia areata, vitiligo, and alopecia Universalis, among others, with good results [2, 3]; in neurology, it has been used to treat chronic inflammatory demyelinating polyneuropathy [4]. An exciting work by Luetic et al. [5], from Argentina, that, in times of Covid, with the impossibility of performing conventional pulse therapy, OPT has been used to treat multiple sclerosis with good efficacy. In hematology, this is one of the first-line treatments for idiopathic thrombocytopenic purpura [6]. However, in rheumatology, this form of treatment is not well known. A review of the literature points to only four studies: two in inflammatory myositis (with a total of 70 observed patients), one in rheumatoid arthritis (with 14 patients), and one in systemic lupus erythematosus (with the observation of 50 patients) [7–9]. They are summarized in Appendix 1. The analysis of this table shows that OPT is at least as effective as other forms of glucocorticoid administration, with apparently fewer side effects than continuous oral use. However, the existing studies are few with small samples, justifying more extensive and long-term controlled trials to compare with standard treatment forms adequately. OPT remains an option to be explored in rheumatology.